Arbutus Announces FDA Clinical Hold is Lifted on IND Application for AB-101, an Oral PD-L1 Inhibitor

Arbutus Announces FDA Clinical Hold is Lifted on IND Application for AB-101, an Oral PD-L1 Inhibitor | Taiwan News | Oct. 22, 2026 19:30

Oct. 22, 2026 19:30

Arbutus Announces FDA Clinical Hold is Lifted on IND Application for AB-101, an Oral PD-L1 Inhibitor

WARMINSTER, Pa., Oct. 22, 2026 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS) (“Arbutus” or the “Company”), a clinical-stage biopharmaceutical company focused on infectious disease, today announced that the Company was notified by the U.S. Food and Drug Administration (“FDA”)…

A hepatitis B hold lifted and drug tabled; Ultomiris' accelerated approval

Plus news about Biohaven, Arcus Biosciences and a Boehringer Ingelheim and Microsoft collaboration. Hold on Arbutus drug lifted: It’s been a long, tough road for Arbutus Biopharma. The company has

Arbutus Biopharma says FDA lifts AB-101 clinical hold

Arbutus says the FDA lifted the AB-101 clinical hold after a Phase 1 study. Further United States development remains under evaluation.